stockrow
Friday 6 November 2026
Export FLGT’s income statement to Excel — free account
Fulgent Genetics, Inc.
FLGT Healthcare Diagnostics & Research
Fulgent Genetics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $322.7 million, up 13.8% from fiscal 2024.
- Revenue
- +7.54%
- EPS
- −128.6%
- Free cash flow
- +2,058.7%
Quarter to September 2026, against a year earlier
22.39
3.73
+19.99%
Follow FLGT
Alert me
| Older periods | Dec '25 | Mar '26 | Jun '26 | Sep '26 From the 10-Q filed 5 Nov | |
|---|---|---|---|---|---|
Piotroski F-Score |
+8 more TTM periods Free account |
4 | 2 | 5 | 5 |
| (5.41%) | (6.81%) | (8.01%) | (8.64%) | ||
| (4.97%) | (6.25%) | (7.37%) | (7.93%) | ||
ROIC |
(7.39%) | (8.62%) | (10.34%) | (8.22%) | |
Return on Tangible Assets |
(10.47%) | (14.61%) | (17.01%) | (21.52%) | |
Average Days of Receivables |
95.88 | 78.93 | 73.17 | 69.06 | |
Free Cash Flow per Share |
(4.04) | (3.66) | (3.71) | 0.52 | |
Free Cash Flow |
(124.21) | (113.16) | (103.78) | 14.43 | |
Capital Expenditures |
(22.57) | (23.05) | (20.08) | — | |
| Other line items | |||||
Cash ROIC |
(8.61%) | (8.57%) | (8.28%) | 1.47% | |
Accounts Receivable Turnover |
4.20 | 4.55 | 4.56 | 4.94 | |
Accounts Payable Turnover |
10.36 | 9.98 | 12.12 | 12.47 | |
Inventory Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
35.50 | 39.27 | 27.21 | 28.34 | |
Days of Inventory on Hand |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
(0.12) | (0.11) | (0.08) | (0.07) | |
Research and Development Expense of Revenue |
16.71% | 17.38% | 17.52% | 17.12% | |
Selling, General and Administrative Expense of Revenue |
49.60% | 51.88% | 52.46% | 52.48% | |
Share Based Compensation of Revenue |
12.27% | 12.15% | 11.58% | 10.87% | |
Interest Coverage |
(1,214.61) | (1,357.99) | (1,019.02) | (1,307.88) | |
Operating CF/Net income |
1.68 | 1.22 | 0.99 | (0.16) | |
Depreciation/Fixed assets |
0.17 | 0.17 | 0.20 | 0.00 | |
Capex/Depreciation |
(1.19) | (1.16) | (0.91) | — | |
Revenue per Share |
10.48 | 10.37 | 11.57 | 11.94 | |
Operating CF per Share |
(3.30) | (2.92) | (2.99) | 0.52 | |
Capex per Share |
(0.73) | (0.75) | (0.72) | 0.00 | |
Capex to Sales |
0.07 | 0.07 | 0.06 | 0.00 |
Columns are period end dates · fundamentals updated 5 Nov 2026